LONG TERM IMMUNE MEMORY RESPONSES TO HUMAN PAPILLOMAVIRUS (HPV) VACCINATION FOLLOWING 2 VERSUS 3 DOSES OF QUADRIVALENT HPV VACCINE

Registry ID

MERCK08-001

Source registry

HEALTH_CANADA

Status

Pending

Study type

INTERVENTIONAL

Sponsor

VACCINE EVALUATION CENTER, UNIVERSITY OF BRITISH COLOMBIA

Last update

2016-06-10

Conditions

• HUMAN PAPILLOMA VIRUS (HPV)
• IMMUNIZATION

Related clinical trials

• MOLECULAR RESIDUAL DISEASE INTERCEPTION IN LOCOREGIONALLY-ADVANCED HIGH RISK HPV+ AND HPV- HNSCC (MERIDIAN)
• A PHASE 3 DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL TO COMPARE THE IMMUNOGENICITY AND SAFETY OF A THREE-DOSE REGIMEN OF SCI-B-VAC TO A THREE-DOSE REGIMEN OF ENGERIX-B IN ADULTS
• A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL TO ASSESS THE LOT-TO-LOT CONSISTENCY OF SCI-B-VAC IN ADULTS
• A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER
• VACCINATING CHILDREN AFTER CHEMOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKEMIA
• A PHASE IV, OPEN-LABEL, NON-RANDOMISED, MULTICENTRE STUDY TO ASSESS THE LONG-TERM PERSISTENCE OF IMMUNITY TO HEPATITIS B IN ADULTS VACCINATED 20 TO 30 YEARS AGO WITH 3 OR 4 DOSES OF GSK BIOLOGICALS' HEPATITIS B VACCINE, ENGERIX-B

View on source registry